B. Riley Securities Reiterates Buy on Altimmune, Maintains $20 Price Target

Altimmune Inc -1.54%

Altimmune Inc

ALT

6.38

-1.54%

B. Riley Securities analyst Mayank Mamtani reiterates Altimmune (NASDAQ: ALT) with a Buy and maintains $20 price target.
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via